The overall ratings of four Pharmaceutical stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. In Portfolio Grader’s specific subcategories of Earnings Momentum, Equity, Cash Flow, and Sales Growth, SUPN also gets F’s. For a full analysis of SUPN stock, visit Portfolio Grader.
VIVUS Inc.’s (NASDAQ:VVUS) rating weakens this week, dropping to a D versus last week’s C. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The stock also rates an F in Equity. The stock price has dropped 10.8% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of July 5, 2013, 28.7% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
Slipping from a C to a D rating, Cempra Inc. (NASDAQ:CEMP) takes a hit this week. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CEMP, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics’ (NASDAQ:CORT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.